Drugs / spirulina
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07647874 | Mar 2025 → Apr 2026 | periodontitis | Mansoura University | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05556967 | Aug → Oct 2023 | — | University of Mississippi Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT05524532 | Jul 2023 → Jul 2025 | post-COVID-19 disorder | University of Mississippi Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT05447078 | Jul 2022 → Dec 2025 | — | University of Mississippi Medical Center | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02886676 | May 2015 → May 2016 | chronic periodontitis | Tatyasaheb Kore Dental College | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02671695 | Apr 2015 → Apr 2018 | beta-thalassemia major | Tanta University | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Spirulina | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02671695 ↗ |
| Known as | Immulina | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05556967 ↗ |
| Known as | Immulina TM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05447078 ↗ |
| Action | Inhibit | “inhibitory effects on prostaglandin and leukotriene biosynthesis” NCT02886676 ↗ |
| Modality | Other / unclassified | “a natural dietary supplement” NCT05524532 ↗ |
| Route | Oral | “250 mg/kg/day orally” NCT02671695 ↗ |